Cluster composition

Functions

CategoryNameIntersectionWithQueryPValueGenesInTermGenesInQueryGenesInTermInQueryID
GeneOntologyMolecularFunctionhistone H3 methyltransferase activity

KMT2D NSD2 NSD3

3.15e-0544283GO:0140938
GeneOntologyMolecularFunctionprotein-lysine N-methyltransferase activity

KMT2D NSD2 NSD3

1.16e-0468283GO:0016279
GeneOntologyMolecularFunctionlysine N-methyltransferase activity

KMT2D NSD2 NSD3

1.22e-0469283GO:0016278
GeneOntologyMolecularFunctionhistone methyltransferase activity

KMT2D NSD2 NSD3

1.32e-0471283GO:0042054
GeneOntologyMolecularFunctionhistone H3K36 methyltransferase activity

NSD2 NSD3

1.46e-0413282GO:0046975
GeneOntologyMolecularFunctionhistone H3K4 methyltransferase activity

KMT2D NSD3

3.55e-0420282GO:0042800
GeneOntologyMolecularFunctionprotein methyltransferase activity

KMT2D NSD2 NSD3

3.98e-04103283GO:0008276
GeneOntologyMolecularFunctionN-methyltransferase activity

KMT2D NSD2 NSD3

4.21e-04105283GO:0008170
GeneOntologyMolecularFunctionS-adenosylmethionine-dependent methyltransferase activity

KMT2D NSD2 NSD3

1.76e-03172283GO:0008757
GeneOntologyMolecularFunctionmethyltransferase activity

KMT2D NSD2 NSD3

3.22e-03213283GO:0008168
GeneOntologyMolecularFunctiontransferase activity, transferring one-carbon groups

KMT2D NSD2 NSD3

3.71e-03224283GO:0016741
GeneOntologyMolecularFunctionhistone modifying activity

KMT2D NSD2 NSD3

3.95e-03229283GO:0140993
GeneOntologyMolecularFunctionmethylated histone binding

ATRX PHF19

6.44e-0386282GO:0035064
GeneOntologyMolecularFunctionmethylation-dependent protein binding

ATRX PHF19

6.74e-0388282GO:0140034
GeneOntologyMolecularFunctionphosphoric diester hydrolase activity

SMPD3 PLCH1

8.13e-0397282GO:0008081
DomainZF_PHD_2

KMT2D ATRX PHF19 NSD2 NSD3

3.94e-0795305PS50016
DomainZF_PHD_1

KMT2D ATRX PHF19 NSD2 NSD3

4.16e-0796305PS01359
DomainPost-SET_dom

KMT2D NSD2 NSD3

2.06e-0616303IPR003616
DomainPostSET

KMT2D NSD2 NSD3

2.06e-0616303SM00508
DomainPOST_SET

KMT2D NSD2 NSD3

2.06e-0616303PS50868
DomainZnf_FYVE_PHD

KMT2D ATRX PHF19 NSD2 NSD3

3.43e-06147305IPR011011
DomainPHD

KMT2D PHF19 NSD2 NSD3

6.07e-0675304PF00628
DomainZnf_PHD-finger

KMT2D PHF19 NSD2 NSD3

7.47e-0679304IPR019787
DomainPHD

KMT2D PHF19 NSD2 NSD3

1.20e-0589304SM00249
DomainZnf_PHD

KMT2D PHF19 NSD2 NSD3

1.31e-0591304IPR001965
DomainAWS

NSD2 NSD3

2.49e-055302PS51215
DomainAWS_dom

NSD2 NSD3

2.49e-055302IPR006560
DomainAWS

NSD2 NSD3

2.49e-055302SM00570
DomainSET

KMT2D NSD2 NSD3

3.83e-0541303PF00856
DomainSET

KMT2D NSD2 NSD3

5.42e-0546303SM00317
Domain-

KMT2D ATRX PHF19 NSD2 NSD3 RNF170

6.79e-054493063.30.40.10
DomainSET_dom

KMT2D NSD2 NSD3

6.97e-0550303IPR001214
DomainSET

KMT2D NSD2 NSD3

6.97e-0550303PS50280
DomainZnf_RING/FYVE/PHD

KMT2D ATRX PHF19 NSD2 NSD3 RNF170

7.67e-05459306IPR013083
DomainRING

KMT2D ATRX NSD2 NSD3 RNF170

1.15e-04305305SM00184
DomainZinc_finger_PHD-type_CS

PHF19 NSD2 NSD3

1.53e-0465303IPR019786
DomainZnf_RING

KMT2D ATRX NSD2 NSD3 RNF170

1.56e-04326305IPR001841
DomainPWWP

NSD2 NSD3

4.65e-0420302SM00293
DomainPWWP

NSD2 NSD3

6.18e-0423302PF00855
DomainPWWP_dom

NSD2 NSD3

6.18e-0423302IPR000313
DomainPWWP

NSD2 NSD3

6.73e-0424302PS50812
DomainHMG_box

KMT2D NSD2

3.27e-0353302PF00505
DomainHMG

KMT2D NSD2

3.39e-0354302SM00398
Domain-

KMT2D NSD2

3.51e-03553021.10.30.10
DomainHMG_box_dom

KMT2D NSD2

4.87e-0365302IPR009071
PathwayREACTOME_PKMTS_METHYLATE_HISTONE_LYSINES

KMT2D NSD2 NSD3

4.79e-0546223MM14933
PathwayREACTOME_PKMTS_METHYLATE_HISTONE_LYSINES

KMT2D NSD2 NSD3

1.69e-0470223M27231
Pubmed

Targeting H3K36 methyltransferases NSDs: a promising strategy for tumor targeted therapy.

NSD2 NSD3

7.19e-07230234083510
Pubmed

Melphalan-induced apoptosis of EBV-transformed B cells through upregulation of TAp73 and XAF1 and nuclear import of XPA.

XAF1 XPA

2.16e-06330224249729
Pubmed

The methyltransferase NSD3 has chromatin-binding motifs, PHD5-C5HCH, that are distinct from other NSD (nuclear receptor SET domain) family members in their histone H3 recognition.

NSD2 NSD3

2.16e-06330223269674
Pubmed

The NSD family of protein methyltransferases in human cancer.

NSD2 NSD3

2.16e-06330225942451
Pubmed

Molecular basis of nucleosomal H3K36 methylation by NSD methyltransferases.

NSD2 NSD3

2.16e-06330233361816
Pubmed

The role of NSD1, NSD2, and NSD3 histone methyltransferases in solid tumors.

NSD2 NSD3

2.16e-06330235532818
Pubmed

Characterization of a novel WHSC1-associated SET domain protein with H3K4 and H3K27 methyltransferase activity.

NSD2 NSD3

2.16e-06330216682010
Pubmed

The histone methyltransferase activity of WHISTLE is important for the induction of apoptosis and HDAC1-mediated transcriptional repression.

NSD2 NSD3

2.16e-06330217239852
Pubmed

DICER- and MMSET-catalyzed H4K20me2 recruits the nucleotide excision repair factor XPA to DNA damage sites.

XPA NSD2

2.16e-06330229233865
Pubmed

Interaction between alpha-COP and SMN ameliorates disease phenotype in a mouse model of spinal muscular atrophy.

COPA GRM7

4.31e-06430231060774
Pubmed

Histone and DNA binding ability studies of the NSD subfamily of PWWP domains.

NSD2 NSD3

4.31e-06430234271259
Pubmed

Systematic perturbations of SETD2, NSD1, NSD2, NSD3, and ASH1L reveal their distinct contributions to H3K36 methylation.

NSD2 NSD3

7.18e-06530239390582
Pubmed

In vitro histone lysine methylation by NSD1, NSD2/MMSET/WHSC1 and NSD3/WHSC1L.

NSD2 NSD3

7.18e-06530225494638
Pubmed

H4K20me0 recognition by BRCA1-BARD1 directs homologous recombination to sister chromatids.

EPC2 NUP214 KMT2D COPA ATRX INTS7 NSD2 NSD3

1.01e-05129430830804502
Pubmed

Hypermutation of immunoglobulin genes in memory B cells of DNA repair-deficient mice.

XPA ATRX

2.01e-0583029607915
Pubmed

Dynamic Protein Interactions of the Polycomb Repressive Complex 2 during Differentiation of Pluripotent Cells.

NUP214 KMT2D ATRX PHF19 CRISPLD1

4.71e-0546930527634302
Pubmed

Transcription mapping and expression analysis of candidate genes in the vicinity of the mouse Loop-tail mutation.

CD48 COPA

5.58e-051330210920231
Pubmed

A PWWP Domain of Histone-Lysine N-Methyltransferase NSD2 Binds to Dimethylated Lys-36 of Histone H3 and Regulates NSD2 Function at Chromatin.

NSD2 NSD3

6.50e-051430226912663
Pubmed

ATRX proximal protein associations boast roles beyond histone deposition.

ATRX NSD2 NSD3

6.68e-059130334780483
Pubmed

Interactome Rewiring Following Pharmacological Targeting of BET Bromodomains.

PLCH1 ATRX INTS7 NSD2 NSD3

8.61e-0553330530554943
Pubmed

Comparative physical and transcript maps of approximately 1 Mb around loop-tail, a gene for severe neural tube defects on distal mouse chromosome 1 and human chromosome 1q22-q23.

CD48 COPA

1.64e-042230211401431
Pubmed

The functional interactome of PYHIN immune regulators reveals IFIX is a sensor of viral DNA.

COPA ATRX NSD2 IKZF5

2.22e-0434930425665578
Pubmed

The Epigenetic Factor Landscape of Developing Neocortex Is Regulated by Transcription Factors Pax6→ Tbr2→ Tbr1.

KMT2D ATRX PHF19

3.35e-0415730330186101
Pubmed

Proximity-dependent biotin identification (BioID) reveals a dynamic LSD1-CoREST interactome during embryonic stem cell differentiation.

GREB1L NUP214 KMT2D ZNF280D

4.40e-0441830434709266
Pubmed

Hdac4 Interactions in Huntington's Disease Viewed Through the Prism of Multiomics.

NUP214 COPA ATRX INTS7

7.11e-0447530431040226
Pubmed

Physical and transcriptional map of a 3-Mb region of mouse chromosome 1 containing the gene for the neural tube defect mutant loop-tail (Lp).

CD48 COPA

8.25e-044930210051400
InteractionNUP43 interactions

XPA NUP214 KMT2D ZNF280D GRM7 NSD2 NSD3

2.30e-05625297int:NUP43
CytobandEnsembl 112 genes in cytogenetic band chr1q23

CD48 BCAN COPA

4.33e-04226303chr1q23
CytobandEnsembl 112 genes in cytogenetic band chr8p11

NSD3 RNF170

2.08e-03103302chr8p11
GeneFamilyPHD finger proteins

KMT2D PHF19 NSD2 NSD3

3.92e-069022488
GeneFamilyZinc fingers C2H2-type|Lysine methyltransferases|PR/SET domain family

KMT2D NSD2 NSD3

9.13e-0634223487
GeneFamilyPWWP domain containing

NSD2 NSD3

3.22e-04222221147
GeneFamilyAdenosine receptors|V-set domain containing

CD48 BCAN

1.66e-02163222590
CoexpressionAtlasDevelopingGonad_e16.5_epididymis_emap-29702_k-means-cluster#4_top-relative-expression-ranked_200

FLRT2 COPA ATRX GRM7

2.91e-0676284gudmap_developingGonad_e16.5_epididymis_200_k4
CoexpressionAtlasDevelopingKidney_e15.5_Cap mesenchyme_emap-27738_top-relative-expression-ranked_1000

GXYLT2 NUP214 PLCH1 ATRX CRISPLD1 NSD2 NSD3 NAA16

5.12e-06779288gudmap_developingKidney_e15.5_Cap mesenchyme_1000
CoexpressionAtlasDevelopingGonad_e16.5_ovary_emap-9563_top-relative-expression-ranked_1000

GREB1L GXYLT2 FLRT2 COPA ATRX HSF5 NSD3 RNF170

5.95e-06795288gudmap_developingGonad_e16.5_ovary_1000
CoexpressionAtlasDevelopingGonad_e18.5_epididymis_emap-13166_top-relative-expression-ranked_1000

COL4A6 XAF1 FLRT2 COPA ATRX GRM7 CRISPLD1 NSD3

6.17e-06799288gudmap_developingGonad_e18.5_epididymis_1000
CoexpressionAtlasDevelopingGonad_e18.5_epididymis_emap-13166_top-relative-expression-ranked_500

FLRT2 COPA ATRX GRM7 CRISPLD1 NSD3

1.21e-05404286gudmap_developingGonad_e18.5_epididymis_500
CoexpressionAtlasDevelopingGonad_e12.5_ovary_emap-28876_k-means-cluster#3_top-relative-expression-ranked_1000

FLRT2 COPA ATRX NSD2 NSD3

2.80e-05277285gudmap_developingGonad_e12.5_ovary_k3_1000
CoexpressionAtlasDevelopingGonad_e18.5_epididymis_emap-13166_k-means-cluster#3_top-relative-expression-ranked_1000

FLRT2 COPA ATRX GRM7 NSD3

3.00e-05281285gudmap_developingGonad_e18.5_epididymis_1000_k3
CoexpressionAtlasDevelopingGonad_e16.5_epididymis_emap-29702_top-relative-expression-ranked_1000

COL4A6 FLRT2 COPA ATRX GRM7 CRISPLD1 NSD3

5.74e-05790287gudmap_developingGonad_e16.5_epididymis_1000
CoexpressionAtlasDevelopingGonad_e16.5_epididymis_emap-29702_k-means-cluster#2_top-relative-expression-ranked_500

FLRT2 COPA ATRX NSD3

5.79e-05162284gudmap_developingGonad_e16.5_epididymis_500_k2
CoexpressionAtlasDevelopingGonad_e11.5_ovary + mesonephros_emap-3226_k-means-cluster#2_top-relative-expression-ranked_1000

FLRT2 COPA ATRX NSD2 NSD3

5.82e-05323285gudmap_developingGonad_e11.5_ovary + mesonephros_k2_1000
CoexpressionAtlasDevelopingGonad_P2_epididymis_emap-30199_top-relative-expression-ranked_1000

COL4A6 FLRT2 COPA ATRX GRM7 CRISPLD1 RNF170

6.07e-05797287gudmap_developingGonad_P2_epididymis_1000
CoexpressionAtlasDevelopingGonad_e14.5_ epididymis_emap-29141_top-relative-expression-ranked_1000

FLRT2 ZNF280D COPA ATRX GRM7 NSD3 RNF170

6.26e-05801287gudmap_developingGonad_e14.5_ epididymis_1000
CoexpressionAtlasDevelopingGonad_e16.5_epididymis_emap-29702_top-relative-expression-ranked_200

FLRT2 COPA ATRX GRM7

6.37e-05166284gudmap_developingGonad_e16.5_epididymis_200
CoexpressionAtlasDevelopingGonad_e18.5_epididymis_emap-13166_top-relative-expression-ranked_200

FLRT2 ATRX GRM7 CRISPLD1

6.37e-05166284gudmap_developingGonad_e18.5_epididymis_200
CoexpressionAtlasDevelopingGonad_e12.5_ovary_emap-28876_top-relative-expression-ranked_1000

GREB1L FLRT2 ZNF280D COPA ATRX NSD2 NSD3

6.41e-05804287gudmap_developingGonad_e12.5_ovary_1000
CoexpressionAtlasDevelopingGonad_e11.5_ovary + mesonephros_emap-3226_k-means-cluster#4_top-relative-expression-ranked_500

FLRT2 COPA ATRX NSD3

7.31e-05172284gudmap_developingGonad_e11.5_ovary + mesonephros_k4_500
CoexpressionAtlasfacebase_RNAseq_e14.5_palate_poster_distal_ERK2_WT_2500_K1

GREB1L GXYLT2 XPA FLRT2 ZNF280D ATRX NAA16 RNF170

9.35e-051166288facebase_RNAseq_e14.5_palate_poster_distal_ERK2_WT_2500_K1
CoexpressionAtlasDevelopingGonad_e16.5_epididymis_emap-29702_k-means-cluster#5_top-relative-expression-ranked_1000

COL4A6 ATRX GRM7 CRISPLD1

1.24e-04197284gudmap_developingGonad_e16.5_epididymis_1000_k5
CoexpressionAtlasDevelopingGonad_e16.5_epididymis_emap-29702_top-relative-expression-ranked_500

FLRT2 COPA ATRX GRM7 NSD3

1.70e-04406285gudmap_developingGonad_e16.5_epididymis_500
CoexpressionAtlasDevelopingKidney_e15.5_Podocyte cells_emap-27915_top-relative-expression-ranked_500

CD48 GXYLT2 FLRT2 PLCH1 GRM7

1.89e-04415285gudmap_developingKidney_e15.5_Podocyte cells_500
CoexpressionAtlasDevelopingGonad_e11.5_ovary + mesonephros_emap-3226_top-relative-expression-ranked_500

FLRT2 COPA ATRX NSD2 NSD3

1.93e-04417285gudmap_developingGonad_e11.5_ovary + mesonephros_500
CoexpressionAtlasDevelopingGonad_e16.5_epididymis_emap-29702_top-relative-expression-ranked_100

FLRT2 ATRX GRM7

1.95e-0486283gudmap_developingGonad_e16.5_epididymis_100
CoexpressionAtlasDevelopingGonad_e14.5_ ovary_emap-6699_k-means-cluster#3_top-relative-expression-ranked_1000

FLRT2 COPA ATRX NSD3

2.06e-04225284gudmap_developingGonad_e14.5_ ovary_1000_k3
CoexpressionAtlasDevelopingGonad_e16.5_ovary_emap-9563_k-means-cluster#2_top-relative-expression-ranked_1000

FLRT2 COPA ATRX NSD3

2.24e-04230284gudmap_developingGonad_e16.5_ovary_1000_k2
CoexpressionAtlasDevelopingGonad_e18.5_epididymis_emap-13166_k-means-cluster#5_top-relative-expression-ranked_1000

COL4A6 XAF1 ATRX CRISPLD1

2.39e-04234284gudmap_developingGonad_e18.5_epididymis_1000_k5
CoexpressionAtlasDevelopingKidney_e15.5_Cap mesenchyme_emap-27738_k-means-cluster#1_top-relative-expression-ranked_1000

GXYLT2 PLCH1 NSD2 NSD3

2.67e-04241284gudmap_developingKidney_e15.5_Cap mesenchyme_1000_k1
CoexpressionAtlasDevelopingGonad_P2_epididymis_emap-30199_k-means-cluster#3_top-relative-expression-ranked_1000

FLRT2 COPA ATRX GRM7

3.03e-04249284gudmap_developingGonad_P2_epididymis_1000_k3
CoexpressionAtlasDevelopingGonad_e12.5_epididymis_emap-29139_k-means-cluster#3_top-relative-expression-ranked_1000

FLRT2 COPA ATRX NSD3

3.52e-04259284gudmap_developingGonad_e12.5_epididymis_k3_1000
CoexpressionAtlasFacebaseRNAseq_e10.5_Lateral Nasal Eminence_top-relative-expression-ranked_1000_k-means-cluster#3

LSS XPA ZNF280D ATRX

5.46e-04291284Facebase_RNAseq_e10.5_Lateral Nasal Eminence_1000_K3
CoexpressionAtlasDevelopingGonad_e11.5_ovary + mesonephros_emap-3226_top-relative-expression-ranked_1000

FLRT2 ZNF280D COPA ATRX NSD2 NSD3

5.73e-04815286gudmap_developingGonad_e11.5_ovary + mesonephros_1000
CoexpressionAtlasfacebase_RNAseq_e14.5_palate_poster_oral_Tgfbr2_WT_2500_K4

GREB1L GXYLT2 XPA FLRT2 ZNF280D ATRX CRISPLD1

5.76e-041148287facebase_RNAseq_e14.5_palate_poster_oral_Tgfbr2_WT_2500_K4
CoexpressionAtlasDevelopingGonad_e16.5_epididymis_emap-29702_k-means-cluster#2_top-relative-expression-ranked_100

FLRT2 GRM7

6.21e-0428282gudmap_developingGonad_e16.5_epididymis_100_k2
CoexpressionAtlasDevelopingKidney_e15.5_Podocyte cells_emap-27915_top-relative-expression-ranked_1000

CD48 GXYLT2 FLRT2 PLCH1 ATRX GRM7

6.55e-04836286gudmap_developingKidney_e15.5_Podocyte cells_1000
CoexpressionAtlasDevelopingGonad_P2_epididymis_emap-30199_k-means-cluster#2_top-relative-expression-ranked_500

FLRT2 COPA ATRX

7.49e-04136283gudmap_developingGonad_P2_epididymis_500_k2
CoexpressionAtlasfacebase_RNAseq_e10.5_MaxArch_2500_K3

GREB1L EPC2 ZNF280D ATRX CRISPLD1 NSD3 NAA16

9.65e-041252287facebase_RNAseq_e10.5_MaxArch_2500_K3
CoexpressionAtlasDevelopingGonad_e12.5_epididymis_emap-29139_k-means-cluster#5_top-relative-expression-ranked_500

FLRT2 COPA ATRX

9.94e-04150283gudmap_developingGonad_e12.5_epididymis_k5_500
CoexpressionAtlasDevelopingKidney_e15.5_Podocyte cells_emap-27915_k-means-cluster#3_top-relative-expression-ranked_200

GXYLT2 PLCH1

1.03e-0336282gudmap_developingKidney_e15.5_Podocyte cells_200_k3
CoexpressionAtlasDevelopingGonad_e18.5_epididymis_emap-13166_k-means-cluster#4_top-relative-expression-ranked_500

FLRT2 COPA GRM7

1.03e-03152283gudmap_developingGonad_e18.5_epididymis_500_k4
CoexpressionAtlasDevelopingKidney_e15.5_Podocyte cells_emap-27915_top-relative-expression-ranked_200

CD48 GXYLT2 PLCH1

1.20e-03160283gudmap_developingKidney_e15.5_Podocyte cells_200
CoexpressionAtlasDevelopingGonad_e12.5_ovary_emap-28876_k-means-cluster#3_top-relative-expression-ranked_500

FLRT2 COPA ATRX

1.22e-03161283gudmap_developingGonad_e12.5_ovary_k3_500
CoexpressionAtlasDevelopingGonad_e14.5_ epididymis_emap-29141_top-relative-expression-ranked_200

FLRT2 COPA ATRX

1.35e-03167283gudmap_developingGonad_e14.5_ epididymis_200
CoexpressionAtlasDevelopingGonad_P2_epididymis_emap-30199_top-relative-expression-ranked_500

FLRT2 COPA ATRX CRISPLD1

1.70e-03395284gudmap_developingGonad_P2_epididymis_500
CoexpressionAtlasDevelopingKidney_e15.5_Cap mesenchyme_emap-27738_top-relative-expression-ranked_500

GXYLT2 NUP214 PLCH1 CRISPLD1

1.79e-03401284gudmap_developingKidney_e15.5_Cap mesenchyme_500
CoexpressionAtlasFacebaseRNAseq_e10.5_Neural Epithelium Overlying Medial Eminence_top-relative-expression-ranked_1000_k-means-cluster#3

EPC2 ZNF280D ATRX

1.82e-03185283Facebase_RNAseq_e10.5_Neural Epithelium Overlying Medial Eminence_1000_K3
CoexpressionAtlasDevelopingGonad_e12.5_epididymis_emap-29139_top-relative-expression-ranked_500

GREB1L FLRT2 COPA ATRX

1.82e-03403284gudmap_developingGonad_e12.5_epididymis_500
CoexpressionAtlasDevelopingGonad_e12.5_ovary_emap-28876_top-relative-expression-ranked_500

GREB1L FLRT2 COPA ATRX

1.93e-03409284gudmap_developingGonad_e12.5_ovary_500
DrugSulfamethazine sodium salt [1981-58-4]; Up 200; 13.4uM; MCF7; HT_HG-U133A

GREB1L LSS XAF1 BCAN NUP214 GRM7

1.88e-071963063847_UP
DrugPrilocaine hydrochloride [1786-81-8]; Up 200; 15.6uM; MCF7; HT_HG-U133A

CD48 LSS XAF1 FLRT2 PLCH1

5.65e-061983053624_UP
DrugAjmalicine hydrochloride [4373-34-6]; Up 200; 10.2uM; HL60; HG-U133A

LSS NUP214 IKZF5 NSD3 RNF170

5.65e-061983051748_UP
DrugSulfamethoxypyridazine [80-35-3]; Up 200; 14.2uM; PC3; HT_HG-U133A

LSS XAF1 NUP214 FLRT2 PLCH1

5.65e-061983053711_UP
DrugAstemizole [68844-77-9]; Up 200; 8.8uM; HL60; HG-U133A

LSS ZNF280D NSD3 RNF170

9.80e-051853041365_UP
DrugFenoprofen calcium salt dihydrate [53746-45-5]; Up 200; 7.2uM; PC3; HT_HG-U133A

GREB1L LSS BCAN GRM7

1.09e-041903044274_UP
DrugProglumide [6620-60-6]; Up 200; 12uM; MCF7; HT_HG-U133A

LSS PLCH1 COPA ATRX

1.11e-041913043861_UP
DrugGuaifenesin [93-14-1]; Down 200; 20.2uM; PC3; HT_HG-U133A

GREB1L COL4A6 LSS BCAN

1.15e-041933043814_DN
DrugCarbetapentane citrate [23142-01-0]; Down 200; 7.6uM; HL60; HT_HG-U133A

ZNF280D COPA NSD2 NSD3

1.15e-041933041268_DN
DrugAconitine [302-27-2]; Up 200; 6.2uM; MCF7; HT_HG-U133A

GREB1L BCAN PLCH1 NSD3

1.18e-041943042776_UP
DrugNaringenine [480-41-1]; Down 200; 14.6uM; MCF7; HT_HG-U133A

GREB1L COL4A6 NUP214 FLRT2

1.18e-041943044422_DN
DrugOxymetazoline hydrochloride [2315-02-8]; Down 200; 13.4uM; MCF7; HT_HG-U133A

BCAN NUP214 PLCH1 COPA

1.20e-041953042278_DN
DrugMetoprolol-(+,-) (+)-tartrate salt [56392-17-7]; Down 200; 5.8uM; PC3; HT_HG-U133A

NUP214 COPA ATRX NSD3

1.20e-041953044508_DN
DrugSalsolinol hydrobromide [38221-21-5]; Up 200; 15.4uM; PC3; HT_HG-U133A

COL4A6 LSS GRM7 IKZF5

1.20e-041953044232_UP
DrugGibberellic acid [77-06-5]; Down 200; 11.6uM; PC3; HT_HG-U133A

NUP214 PLCH1 IKZF5 NSD3

1.20e-041953044234_DN
DrugFlunixin meglumine [42461-84-7]; Down 200; 8.2uM; HL60; HT_HG-U133A

FLRT2 COPA NSD2 IKZF5

1.20e-041953042552_DN
DrugBetonicine [515-25-3]; Up 200; 25.2uM; PC3; HT_HG-U133A

COL4A6 LSS FLRT2 NSD3

1.22e-041963043745_UP
DrugPempidine tartrate [546-48-5]; Up 200; 13uM; PC3; HT_HG-U133A

COL4A6 FLRT2 PLCH1 GRM7

1.22e-041963044307_UP
DrugTetracycline hydrochloride [64-75-5]; Up 200; 8.4uM; PC3; HT_HG-U133A

COL4A6 PLCH1 NSD2 IKZF5

1.22e-041963042080_UP
DrugMexiletine hydrochloride [5370-01-4]; Up 200; 18.6uM; MCF7; HT_HG-U133A

CD48 LSS BCAN NUP214

1.25e-041973042324_UP
DrugAcetaminophen [103-90-2]; Up 200; 26.4uM; MCF7; HT_HG-U133A

CD48 XAF1 NUP214 NSD3

1.25e-041973043364_UP
DrugMethiazole; Up 200; 15uM; PC3; HT_HG-U133A

BCAN PLCH1 IKZF5 NSD3

1.25e-041973044532_UP
DrugLithocholic acid [434-13-9]; Up 200; 10.6uM; MCF7; HT_HG-U133A

GREB1L LSS FLRT2 COPA

1.25e-041973043899_UP
DrugIopamidol [60166-93-0]; Down 200; 5.2uM; MCF7; HT_HG-U133A

LSS PLCH1 IKZF5 RNF170

1.25e-041973043473_DN
DrugNeomycin sulfate [1405-10-3]; Up 200; 4.2uM; MCF7; HT_HG-U133A

GREB1L BCAN PLCH1 GRM7

1.25e-041973042229_UP
DrugDeoxycorticosterone [64-85-7]; Up 200; 12.2uM; MCF7; HT_HG-U133A

PLCH1 GRM7 NSD2 NSD3

1.27e-041983046476_UP
DrugEtodolac [41340-25-4]; Up 200; 14uM; MCF7; HT_HG-U133A

LSS ZNF280D INTS7 NAA16

1.27e-041983047006_UP
DrugButylparaben [94-26-8]; Down 200; 20.6uM; MCF7; HT_HG-U133A

BCAN PLCH1 ATRX NSD3

1.27e-041983046446_DN
Drug15(S)-15-methyl Prostaglandin E2; Down 200; 10uM; MCF7; HT_HG-U133A

CD48 BCAN FLRT2 NSD3

1.27e-041983047489_DN
DrugDeltaline [6836-11-9]; Up 200; 7.8uM; MCF7; HT_HG-U133A

LSS NUP214 PLCH1 COPA

1.27e-041983043831_UP
Drug0179445-0000 [211246-22-9]; Up 200; 1uM; MCF7; HT_HG-U133A

CD48 XAF1 FLRT2 PLCH1

1.30e-041993043633_UP
DrugPheniramine maleate [132-20-7]; Up 200; 11.2uM; MCF7; HT_HG-U133A

GREB1L PLCH1 ATRX NAA16

1.32e-042003041492_UP
DrugRacecadotril [81110-73-8]; Up 200; 10.4uM; PC3; HT_HG-U133A

CD48 COL4A6 IKZF5 NSD3

1.32e-042003045755_UP
DrugKarakoline [39089-30-0]; Up 200; 10.6uM; PC3; HT_HG-U133A

COL4A6 XAF1 NUP214 PLCH1

1.32e-042003043741_UP
Drugchlorcyclizine

LSS SMPD3 ATRX

2.03e-0487303ctd:C084597
DiseaseSotos syndrome 1 (implicated_via_orthology)

NSD2 NSD3

3.00e-063302DOID:0112103 (implicated_via_orthology)
DiseaseMicrocephaly

LSS NUP214 NSD2

4.35e-0567303C0025958
Diseaseintellectual disability (implicated_via_orthology)

ZNF280D ATRX NAA16

6.09e-0575303DOID:1059 (implicated_via_orthology)
DiseaseMuscle hypotonia

LSS NSD2

1.35e-0417302C0026827
Diseasesyndrome (implicated_via_orthology)

NSD2 NSD3

1.51e-0418302DOID:225 (implicated_via_orthology)
Diseaselung small cell carcinoma (is_implicated_in)

KMT2D ATRX

3.72e-0428302DOID:5409 (is_implicated_in)
DiseaseHematopoetic Myelodysplasia

SMPD3 ATRX

3.99e-0429302C2713368
DiseaseDrug-induced agranulocytosis, response to clozapine

GRM7 INTS7

8.39e-0442302GO_0097338, HP_0012235
DiseaseL2 Acute Lymphoblastic Leukemia

NUP214 NSD2

1.19e-0350302C0023453
DiseaseChildhood Acute Lymphoblastic Leukemia

NUP214 NSD2

1.28e-0352302C0023452
DiseasePrecursor Cell Lymphoblastic Leukemia Lymphoma

NUP214 NSD2

1.76e-0361302C1961102
DiseaseMYELODYSPLASTIC SYNDROME

SMPD3 ATRX

2.12e-0367302C3463824
Diseasecongenital heart disease (implicated_via_orthology)

KMT2D NAA16

2.25e-0369302DOID:1682 (implicated_via_orthology)
DiseaseMalignant Glioma

XAF1 ATRX

2.31e-0370302C0555198
Diseasemixed gliomas

XAF1 ATRX

2.31e-0370302C0259783

Protein segments in the cluster

PeptideGeneStartEntry
MPYVCQVCNYRSSSF

ZNF280D

416

Q6N043
CQYYAPRLDQANHSC

EPC2

406

Q52LR7
TMPFIYCNINEVCHY

COL4A6

1521

Q14031
YTDCHIPNNMRYCNS

FLRT2

636

O43155
YTPVSYMHTACLCNA

INTS7

766

Q9NVH2
SDVPCNYHLSYTCKM

BCAN

796

Q96GW7
CSSQYEEYRMACHNL

NAA16

816

Q6N069
YSRFMNHSCQPNCET

NSD2

1136

O96028
NYRPDHCMYGSNCRE

GXYLT2

336

A0PJZ3
CHCRQVYLPMSYCYA

LSS

231

P48449
MEPCYGSCTERQHHY

NUP214

291

P35658
DCYVAICNPLQYHTM

OR5K3

121

A6NET4
MDVAYHCYPNKCNDD

SMPD3

416

Q9NY59
YNTFHHCEQCRQYMD

GREB1L

1436

Q9C091
CQHCDMYFADNILYT

IKZF5

366

Q9H5V7
IMDENNQWYCYICHP

ATRX

256

P46100
YQLNYDMHNPFDICA

COPA

1156

P53621
SCYQHRECSMPSAYT

C19orf71

96

A6NCJ1
VYCPRNCMQANPHYA

CRISPLD1

416

Q9H336
YQYQFDEMTCQHCPY

GRM7

551

Q14831
CHTSCYYPRTHMLCN

KRTAP13-3

76

Q3SY46
MPHNYSRCYTCQVSN

CD48

186

P09326
SSYAHCNYFQNPSMQ

HSF5

331

Q4G112
SDPQCQNYCNMSDTR

NTN5

341

Q8WTR8
FYTDMYCPICLHQAS

RNF170

81

Q96K19
APEREIYCHYCNQMI

XAF1

146

Q6GPH4
DSPHRTNQQQCYCYC

PHF19

186

Q5T6S3
GNYSRFMNHSCNPNC

NSD3

1216

Q9BZ95
MDQPLCNYYIASSHN

PLCH1

301

Q4KWH8
YLMNHFDLPTCDNCR

XPA

116

P23025
TSSCNRMRCPNVYHF

KMT2D

5101

O14686